Shou-jie J. Huang
State Key Laboratory Of Vaccines For Infectious Diseases
Xiamen, China
Xiamen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: November 28, 2025
Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.
Journal: Nature communications
Published: July 29, 2025
Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: April 11, 2025
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3-17 years.
Journal: NPJ vaccines
Published: July 09, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
Journal: The Lancet. Infectious diseases
Published: December 03, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Journal: The Lancet. Infectious diseases
Published: March 14, 2023
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: February 06, 2023
Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: December 04, 2022
Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study.
Journal: Emerging microbes & infections
Published: October 31, 2022
Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial.
Journal: Human vaccines & immunotherapeutics
Published: July 14, 2022
Prognosis of hepatitis E infection in patients with chronic liver disease: A meta-analysis.
Journal: Journal of viral hepatitis
Published: June 17, 2022
Last Updated: 09/26/2026